Reuters logo
BRIEF-Novelion Therapeutics says CEO resigns, posts Q3 results
November 9, 2017 / 1:56 PM / a month ago

BRIEF-Novelion Therapeutics says CEO resigns, posts Q3 results

Nov 9 (Reuters) - Novelion Therapeutics Inc

* Novelion Therapeutics reports third quarter 2017 financial results and announces leadership change

* Sees FY 2017 revenue $135 million to $145 million

* Q3 revenue $28.7 million

* Novelion Therapeutics Inc - ‍Company reiterates FY 2017 guidance for total net revenues of $135-$145 million​

* Novelion Therapeutics Inc - ‍Chief Executive Officer Mary Szela has resigned for personal reasons, effective immediately​

* Novelion Therapeutics Inc - ‍Board announced creation of an interim office of chief executive officer​

* Qtrly loss per share $2.67 ‍​

* Novelion Therapeutics Inc - ‍Continues to anticipate EMA approval for Metreleptin​ in first half of 2018 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below